Erastin, an exogenic small-molecule inducer of ferroptosis, not only promotes iron accumulation in cells by improving transferrin receptor 1 (TFR1) expression but also reduces cellular GSH levels by directly suppressing the activity of system Xc-, and it has been developed as an agent to treating various cancers, including NSCLC [92]. Here, TFRC is linked to cancer.